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Figure 1. Cumulative incidence of allo-LS for BAL-RV positive, NPA-RV positive
and RV negative patients
Figure 2. Cumulative incidence of allo-LS for Rhinovirus positive,
non-Rhinovirus positive and RV negative patients.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S54eS78 S55Results: 178 patients were included, median age 6.8 yr
(0.6-22.7), transplanted for leukemia/lymphoma (51%), bone
marrow failure syndromes (9%), primary immune deﬁciency
(PID) (18%) and non-PID benign disorders (22%). Myelo-
ablative conditioning regimen was used; chemotherapy
based in 85%, containing Total Body Irradiation in 15%. Do-
nors used: Matched family (26%), unrelated cord blood (54%)
and unrelated bone marrow (20%). In 57% of patients pre-
HCT NPA was positive for RV. RV was detected in 40% of BAL
samples. In 37% of NPA-RV positive patients BAL was nega-
tive, whereas only 7% of BAL positives were NPA negative.
Rhinovirus was the most frequently detected virus (43%).There was a similar distribution of the various viruses in
BAL and NPA. Most patients had no or very mild signs
of upper respiratory tract infection at time of sampling.
In multivariate analyses BAL RV positivity was the
only predictor associated with allo-LS: HR 3.89, 95% CI
1.41e10.40; p¼0.009). NPA-only positivity was not
associated with allo-LS (Fig. 1). No signiﬁcant difference was
found between Rhino- and nonRhino virus in the risk for
allo-LS (Fig. 2).
Conclusion: RV positivity is frequently seen in pediatric
patients pre-HCT. Rhinovirus was the most commonly found
RV. RV positivity in BAL pre-HCT is a strong predictor for
allo-LS in children post-HCT. This association was similar for
Rhino- and nonRhinovirus positive patients. These data
support the importance of identifying patients at risk for
allo-LS by pre-HCT BAL. Early recognition may guide
preventive strategies: e.g. postponement of elective HCTs
and delayed tapering of immune-suppression.38
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We previously showed that adoptive transfer of 3 million
Treg per kilogram recipient body weight could reduce the
risk of acute GVHD (aGVHD) (39% vs. 61%, p-0.05; Blood
117:1061) in recipients of double UCBT. We hypothesized
that control of GVHD was suboptimal, likely related to the
low ratio of Treg to T cells in the UCB graft (i.e., 0.3:1.0). Our
group previously demonstrated optimal murine GVHD con-
trol with Treg:Teffector ratio  1:1. A genetically modiﬁed
K562 cell line, termed KT64/86, that expressed CD64, a high
afﬁnity Fc receptor loaded with anti-CD3 antibody, and
CD86, the natural ligand of CD28/CTLA-4, was used to
manufacture higher doses of Treg from a single UCB unit, that
retained the CD4+CD25+FoxP3+ CD127- phenotype and
had potent in vitro and in vivo (murine xenogeneic) sup-
pression of T cell proliferation. Using this methodology, we
performed a phase I dose escalation trial starting with 3
million donor Treg/kg. Patients who were candidates for
nonmyeloablative double UCBT were eligible. Ten patients
received Cy50/FLU200/TBI200 nonmyeloablative condition-
ing with sirolimus and mycophenolate mofetil immuno-
suppression. Thawed Tregs underwent a single CD25 positive
selection and were cultured for 181 days in the presence of
KT64/86 (1:1) supplemented with 300 units/mL rhIL-2;
cultures were restimulated with KT64/86 on day 12. In the
dose escalation, 3 to 100 million Tregs/kg were infused on
day +1 and patients monitored for infusional toxicity and
GVHD. Fifteen concurrent patients received same treatment
regimen but no Treg served as controls for clinical endpoints.
Figure. Cumulative on acute GVHD by day þ100 in patient who did or did not
receive nTregs.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S54eS78S56The median age of Treg-treated patients was 62 (r:45-69), 5
were male, 6 had acute leukemia, 4 had CLL/lymphoma. The
median infused combined nucleated and CD3+ cell doses of
the UCB graft were 4 x10e7 (r:4-9) and 16.5 x 10e6 (r:14-18),
respectively. None had a severe adverse event with the
infusion. One Treg treated patient developed a skin rash on
day +16; biopsy was equivocal for engraftment syndrome to
be conservative we considered as aGVHD. Thus, the inci-
dence of grade 2-4 aGVHD by day +100 was 10% (95% CI, 0-
28%) as compared to 53% (95% CI, 27-79%) in the controls
(p¼.04, Figure). One patient developed grade 3 late gastro-
intestinal aGVHD in the Treg group (day 119). Engraftment
was similar between Treg (90%, 95% CI, 74-99%) and control
(87%, 95% CI, 65-98%) groups (p¼.92). The median follow-up
is too short for assessment of chronic GVHD and relapse. In
summary, we 1) demonstrated the ability to consistently
manufacture Treg doses up to 100 x10 e6/kg which allows
for Treg: T effector ratio of up to 7:1, and 2) observed a
remarkably low risk of aGVHD. This promising result is the
ﬁrst clear demonstration that ex vivo expanded UCB Treg are
potent suppressors of aGVHD in humans and sets the stage
for a future pivotal clinical trial that will assess the clinical
impact of Treg GVHD prophylaxis on immune recovery and
risk of leukemia relapse.39
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Graft versus host disease (GvHD) is the most common
complication of hematopoietic stem cell transplant (HCT).
However, our understanding of the molecular pathways
that cause this disease remains incomplete, leading to
inadequate targeted strategies for prevention and treatment.
To address this, we determined the gene expression proﬁle of
non-human primate (NHP) T cells during active and partially
controlled acute GvHD (aGvHD), in order to accomplish
two goals: 1) uncover important genetic drivers of aGvHDand 2) identify novel, targetable pathways for optimal
aGvHD prevention.
Utilizing microarray technology, we measured the gene
expression proﬁles of ﬂow cytometrically puriﬁed CD3+ T
cells from NHP recipients of MHC partially matched HCT in
three treatment cohorts resulting in increasing degrees of
survival: 1) no immunoprophylaxis (No Rx, MST ¼ 7.5); 2)
sirolimus monotherapy (MST ¼ 17; and 3) tacrolimus-meth-
otrexate (tac-mtx) dual prophylaxis (MST ¼ 49). Arrays were
performed on T cells puriﬁed on Day +14 post-transplant
(unless terminal analysis occurred earlier due to severe dis-
ease). This comparison allowed us to determine the impact of
both mTOR and calcineurin inhibition on the molecular
pathways dysregulated during GvHD, and to determine
which genes and pathways remained dysregulated despite
prophylaxis. Pathways identiﬁed by this strategymay contain
new therapeutic targets unaffected by current immunopro-
phylactic approaches. We found that the transcriptional
proﬁle of donor T cells from HCT recipients with unprophy-
laxed GvHD was characterized by signiﬁcant perturbation of
pathways regulating Tcell proliferation, effector function and
cytokine synthesis. By identifying pathways unaffected by
sirolimus or tac-mtx therapy, we discovered multiple
potentially druggable targets not previously implicated in the
pathophysiology of aGvHD. These targets prominently
included the hedgehog and the aurora kinase A pathways.
Utilizing a murine aGvHD model, we demonstrated that
pharmacologic inhibition of these pathways could mitigate
disease and improve survival.
These data provide the ﬁrst identiﬁcation of the T cell
transcriptome of primate acute GvHD and the hedgehog and
aurora kinase A pathways as novel potential targets for
prevention of this disease.40
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Background: Neovascularization and endothelial dysfunc-
tion are recognized sequelae of acute graft-versus-host
disease (aGVHD). We hypothesized that patients with
abundant angiogenic factors (AF) involved in repair/
regeneration would have improved survival relative to those
with higher levels of AF involved in damage/inﬂammation.
Patients and Methods:Wemeasured circulating levels of AF
known predominantly for repair/regeneration (epidermal
growth factor [EGF], ﬁbroblast growth factor [FGF]-1, FGF-2,
heparin binding-EGF-like growth factor, follistatin [FS],
vascular endothelial growth factor [VEGF]-A, VEGF-C, and
VEGF-D) and those known predominantly for endothelial
dysfunction/inﬂammation (angiopoietin-2 [Ang2], endothe-
lin-1, soluble endoglin [sEng], leptin, placental growth
factor [PlGF]) in HCT recipients with grade III-IV aGVHD
(N¼17) compared to recipients without aGVHD (N¼17) and
healthy stem cell donors (HD, N¼16) in a pilot study. AF
demonstrating <0.5-fold or >1.5-fold difference in median
with p0.1 were validated in two cohorts of patients with
